Market Place
Sourcing Support
Eli Lilly`s Rayvow (lasmiditan) Receives Approval in Europe
03 Oct 2022 //
EMA
Eli Lilly, Daiichi Sankyo partner to commercialize lasmiditan succinate in Japan
31 Aug 2021 //
PHARMABIZ
REYVOW® Positive Data in New Phase 3 Consistency of Effect Study
06 Oct 2020 //
PRNEWSWIRE
Eli Lilly`s Reyvow, squaring off against AbbVie and Biohaven
11 Sep 2020 //
FIERCE PHARMA
Lilly`s migraine med lasmiditan successful in another late-stage study
10 Sep 2020 //
SEEKINGALPHA
ICER comes around on Allergan, Biohaven migraine meds
26 Feb 2020 //
FIERCE PHARMA
Eli Lilly prices migraine therapy at $640 for pack of eight pills
31 Jan 2020 //
REUTERS
With DEA scheduling, Lilly`s Reyvow cleared for launch
31 Jan 2020 //
FIERCE PHARMA
Lilly`s REYVOW™C-V, the First and Only Medicine in Acute Treatment for Migraine
31 Jan 2020 //
PRESS RELEASE
Biohaven celebrates PhII/III win for intranasal CGRP migraine drug with Allergan
17 Dec 2019 //
ENDPT NEWS
ICER Releases Draft Evidence Report on Acute Migraine Therapies
08 Nov 2019 //
ICER
Migraine hopefuls from Lilly, Allergan and Biohaven don`t beat older drugs: ICER
07 Nov 2019 //
FIERCE PHARMA
Eli Lilly next big bet on next-gen pain drug, buying Hydra assets
17 Dec 2018 //
ENDPTS
Lilly Submits NDA to FDA for Lasmiditan, Receives BTH Designation for EmgalitY
15 Nov 2018 //
PR NEWSWIRE
Eli Lilly files for FDA approval of migraine drug lasmiditan
15 Nov 2018 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.